Published
2048 Ventures, Conscience VC, Gaingels, ZAKA VC, Lexi VC, Pareto Holdings, Incite Labs, Meru Capital Group
A new kind of cancer treatment, called CAR-T, trains your immune cells to find and kill cancer, but it mostly works only in blood cancers.
When used on solid tumors like brain cancer, the treatment fails because the tumor creates a toxic environment that shuts immune cells down.
Most companies try to fix this by making the cells stronger, but that can cause dangerous side effects, especially in the brain.
The smarter approach? Make the cells immune to the tumor’s tricks so they can stay focused and finish the job.
This week’s company is building cancer-fighting cells that block the tumor’s defense system before it can stop them.
KiraGen uses AI to design immune cells that can resist the defenses of solid tumors like brain, lung, and breast cancer.
Immune Cells: Special white blood cells reprogrammed to find and destroy cancer.
Solid Tumors: Hard-to-treat cancers that create signals to block or weaken those immune cells.
AI: KiraGen uses machine learning to predict the best gene edits, helping design more effective treatments faster and with fewer failed experiments.
Bulleted Version
Market Opportunity: Solid tumors represent a fast growing, nearly $200B global market with around 19M new cases annually and virtually no durable cell therapies approved to treat them.
Off-the-Shelf: Most cell therapies in solid tumors rely on modifying each patient’s own cells, while KiraGen uses donor cells that are ready-to-use, faster to make, and cheaper to scale.
Closing a Known Gap: Instead of starting from scratch, KiraGen is building directly on clinical signals from early CAR-T trials—designing a solution to the exact failure that’s holding the field back.
Clinical Translation: Strong mouse data is a start, but translating those results into durable responses in humans, especially in GBM, is still unproven.
Scalability Challenge: Even with an off-the-shelf model, manufacturing consistent cell therapies at scale is still an unsolved problem in the field.
Indication Risk: Early setbacks could cast doubt on both the lead program and the broader platform, making early clinical validation critical for investor confidence and downstream partnerships.
Moonlight Bio: Boosts T cell strength using natural mutations, but only targets one gene at a time KiraGen tackles multiple tumor defenses at once.
OverT Bio: Improves T cells by adding a single protein, but lacks KiraGen’s customized, multi-gene approach built around real tumor biology.
Waypoint Bio: Gathers great data to improve CAR design, but doesn’t engineer the whole cell to resist suppression like KiraGen does.
WhyKiraGen
By overcoming tumor defenses known to cause clinical failure, KiraGen is poised to be the biotech company that edits the ending for solid tumors.
*Nothing in this content constitutes investment or legal advice. Conduct independent diligence and consult professional advisers before making investment decisions.*
SF
2026-10-28
Talp is an AI-powered customer simulation platform that helps businesses predict how customers might respond to pricing changes, product launches, and marketing campaigns before making those decisions.
Business model
Annual B2B contracts
NYC
2026-10-13
Snag is a socially-native marketplace for apartments that helps renters discover, verify, and pay for flexible rentals.
Business model
Fees taken on rent processed through the marketplace
NYC
2026-09-29
Ophelia is the discovery, authentication, and transaction layer that lets AI agents securely act on your behalf without relying on web browsers.
Business model
Usage-based API pricing tied to confirmed outcomes